

FILED
CLERK'S OFFICE
7/20/03 11:36

U.S. DISTRICT COURT
DISTRICT OF MASS.

UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

04 11726 WC

IN RE RELAFEN ANTITRUST
LITIGATION

Master File
No. 01-CV-12239-WGY

STATE OF MARYLAND

by Attorney General J. Joseph Curran, Jr.
Office of the Attorney General
Antitrust Division
200 St. Paul Street
Baltimore, MD 21202

STATE OF ARKANSAS

by Attorney General Mike Beebe
Office of the Attorney General
Antitrust Division
323 Center St. Ste. 200
Little Rock, AR 72201

STATE OF IDAHO

by Attorney General Lawrence Wasden
Office of the Attorney General
Len B. Jordan Building
650 W. State St., Lower Level
Boise, ID 83720-0010

STATE OF ILLINOIS

By Attorney General Lisa Madigan
Office of the Attorney General
100 West Randolph Street, 13th Floor
Chicago, Illinois 60601

STATE OF OREGON

By Attorney General Hardy Myers
Oregon Department of Justice
1162 Court Street NE
Salem, Oregon 97301

and)

STATE OF WASHINGTON)
 by Attorney General Christine O. Gregoire)
 Office of the Attorney General)
 900 Fourth Avenue, Suite 2000)
 Seattle, Washington 98164,)

Plaintiffs)

v.)

SmithKline Beecham Corporation)
 One Franklin Plaza)
 16th and Race Streets)
 Philadelphia, PA 19102,)

And)

SmithKline Beecham plc,)
 One Franklin Plaza)
 16th and Race Streets)
 Philadelphia, PA 19102,)

Defendants.)

COMPLAINT

The States of Arkansas, Idaho, Illinois, Maryland, Oregon and Washington (collectively "Plaintiff States" or "States"), by and through their Attorneys General, for their Complaint against Defendant SmithKline Beecham Corporation and SmithKline Beecham plc ("GSK" or "Defendants") to secure damages, injunctive and other equitable relief for Defendants' violations of federal and state antitrust laws, consumer protection, and unfair and deceptive trade practices acts, allege as follows:

I. INTRODUCTION

1. Relafen® is a brand-name prescription drug containing nabumetone as its active pharmaceutical ingredient. Relafen® is a non-steroidal anti-inflammatory drug ("NSAID"), used

to treat diseases characterized by inflammation, and a chemical compound disclosed by U.S. Patent No. 4,420,639 (the "639 Patent"). Prior to August 2001, no other brand-name or generic nabumetone-based drug was marketed in the United States, due to the Defendants' anticompetitive conduct including unlawfully obtaining and enforcing a monopoly for Relafen® and nabumetone-based drugs through intentional misrepresentation to the U.S. Patent and Trade Mark Office ("PTO"). In 2002, GSK's sales of Relafen® in the United States were over \$200 million.

2. Defendants obtained a patent for nabumetone and had it listed in the Food and Drug Administration's (FDA) *Orange Book*, defined below, which enabled Defendants to falsely create and extend their monopoly for Relafen® and nabumetone. Defendants further engaged in sham litigation to unlawfully enforce their patent, even though they knew that the patent was invalid. As a result, consumers were forced to pay more for nabumetone.

3. Plaintiff States seek the following: a) a finding that Defendants' actions violated federal and state antitrust laws, consumer protection laws, unfair competition laws and other related state laws; b) a permanent injunction preventing Defendants from submitting the '639 Patent for listing in the *Orange Book* and from taking other actions similar to those which resulted in the improper delay in generic competition for nabumetone; and c) relief for injuries sustained as a result of Defendants' violations of law.

II. PARTIES

4. Defendant SmithKline Beecham Corporation is a corporation organized and existing under the laws of the commonwealth of Pennsylvania, doing business as GlaxoSmithKline ("SmithKline"). Its principal place of business is at One Franklin Plaza, 16th and Race Streets, Philadelphia, Pennsylvania 19102. SmithKline develops, manufactures, markets, sells, and distributes pharmaceutical products, including Relafen®.

5. Defendant SmithKline Beecham plc is a corporation organized and existing under the laws of the United Kingdom, and is a corporate affiliate of SmithKline Beecham Corporation ("Beecham"). Its principal place of business within the United States is at One Franklin Plaza, 16th and Race Streets, Philadelphia, Pennsylvania 19102. Both SmithKline Beecham Corporation and SmithKline Beecham plc are hereinafter referred to as "GSK" or "Defendants." Defendants manufacture and market Relafen® throughout the United States.

6. Plaintiff States moved to intervene in this case on July 7, 2004, on the grounds that consumers in their states were entitled to recovery under Group I, as defined in the proposed settlement in the above captioned case, and that their Attorneys General have sole authority to recover for harm to natural person consumers. The Plaintiff States bring this action by and through their Attorneys General under statutory, equitable and/or common law authority including but not limited to: (a) federal or state law, in their sovereign capacities, as representatives of, and/or as *parens patriae* on behalf of, or for the benefit of, natural persons who paid for Relafen® or any other nabumetone product during the relevant time period; (b) in their proprietary capacities on behalf of represented entities which may include state departments, bureaus, agencies, political subdivisions, and other government entities as direct or indirect purchasers, and/or as assignees of the antitrust causes of action of intermediate purchasers through which they procured or reimbursed for such drugs, or as purchasers under medical or pharmaceutical reimbursement programs, of such drugs during the relevant time period (hereinafter "State Governmental Entities"); (c) as common law *parens patriae* in their sovereign capacities on behalf of their respective states' general economies; and/or (d) in their capacities as enforcers of state law to enjoin violations, to disgorge unjust profits, and to provide relief for injuries incurred in their states by securing damages and/or restitution, injunctions and other equitable remedies.

III. JURISDICTION AND VENUE

7. Subject matter jurisdiction is proper pursuant to Section 2 of the Sherman Act, 15 U.S.C. § 2, and sections 4, 4C, 12 and 16 of the Clayton Act, 15 U.S.C. §§ 15, 15c, 22 and 26, and under 28 U.S.C. §§ 1331, 1337.

8. In addition to pleading violations of federal antitrust law, the States also allege violations of state antitrust, consumer protection and/or unfair competition statutes and related state laws, as set forth below, and seek damages, civil penalties and/or equitable relief under those state laws. All claims under federal and state law are based upon a common nucleus of operative facts, and the entire action commenced by this Complaint constitutes a single case that would ordinarily be tried in one judicial proceeding. This Court has jurisdiction of the non-federal claims under 28 U.S.C. § 1367(a), and under the principles of supplemental jurisdiction. Supplemental jurisdiction will avoid unnecessary duplication and multiplicity of actions, and should be exercised in the interests of judicial economy, convenience, and fairness.

9. Venue is proper in this Court under Section 12 of the Clayton Act, 15 U.S.C. § 22 and 28 U.S.C. § 1391(b) and (c). Defendants transact business in this district. Further, the claims alleged arose, in whole or in part, in this judicial district, and a substantial portion of the affected trade and commerce described below has been carried out in this judicial district.

IV. STATEMENT OF FACTS

A. Pioneer Drugs

10. Under the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301 *et seq.*, a drug manufacturer must obtain approval from the FDA before the manufacturer may lawfully begin selling a new drug (also called a "pioneer drug") in the United States. 21 U.S.C. § 355(a). In order to obtain FDA approval, the manufacturer must file a New Drug Application ("NDA")

demonstrating that the drug is safe and effective for its intended use. 21 U.S.C. § 355(b) or 355(j).

11. The NDA must contain, among other things, data on the composition of the drug product including its active ingredient, the means for its manufacture, and a statement of its proposed uses. An NDA must list all patents that claim the approved drug where a claim of patent infringement could reasonably be asserted against an unauthorized manufacturer or seller of the drug. 21 U.S.C. § 355(b) and (c)).

12. A pioneer drug is typically covered by one or more patents, which grant the owner the right to exclude others from manufacturing for sale the new drug for the duration of the patent(s) including any extensions of the original patent period granted pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355 ("Hatch Waxman" or "Hatch-Waxman Act").

13. Once the NDA is approved, and upon certification by the brand-name manufacturer that the newly-issued patent meets the listing criteria, the FDA publishes the patent information submitted by the manufacturer in a publication commonly referred to as the *Orange Book*. See 21 U.S.C. § 355(j)(7)(a)(iii) (formally titled, "Approved Drug Products with Therapeutic Equivalent Evaluations"). The FDA has a long-standing, publicly announced policy of accepting at face value the accuracy of patent information it receives from a patent holder, and its eligibility for *Orange Book* filing.

14. Once approved, a new drug may be labeled, marketed and advertised only for FDA-approved uses. A pharmacist filling a prescription must fill the prescription with the drug brand specified by the physician, unless an FDA-approved generic version is available and applicable state law provides for generic substitution.

B. Generic Drugs

15. A generic drug is one that has been approved by the FDA as bioequivalent to a brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use.

16. Generic drugs are usually priced substantially below the brand-name drug. Typically, the first generic drug to be sold is priced at a percentage discount off the brand-name drug price, and even steeper price reductions occur as additional generic versions become available.

17. A brand-name drug generally loses substantial market share to generic competition within a relatively short time after a generic is introduced to the market. Consumers covered by some form of insurance or benefit plan often switch to a generic bioequivalent and may be encouraged to do so by virtue of a lower co-payment for generics. Consumers who pay cash for prescriptions also switch from brand-name to generic drugs to obtain the lower price.

18. A principal goal of Hatch Waxman was to facilitate generic competition by streamlining the process by which manufacturers of generic drugs receive regulatory approval to bring their products to market. See *Mova Pharmaceuticals Corp. v. Shalala*, 140 F.3d 1060, 1068 (D.C. Cir. 1998). Under Hatch Waxman, a company may seek expedited FDA approval to market a generic version of a brand-name drug with an approved NDA by filing an Abbreviated New Drug Application ("ANDA") pursuant to 21 U.S.C. § 355(j). An ANDA filer relies on the safety and efficacy data already filed with the FDA by the brand-name manufacturer. 21 U.S.C. § 355(j)(2)(A)(I).

19. In its ANDA, a generic manufacturer generally must certify to the FDA that one of the following conditions is satisfied: (i) no patent covering the drug has been filed with the FDA ("Paragraph I Certification"); (ii) the patent for the brand-name drug has expired

("Paragraph II Certification"); (iii) the patent for the brand-name drug will expire on a particular date, and the generic company does not seek to market its generic product before that date ("Paragraph III Certification"); or (iv) the patent for the brand-name drug is invalid or will not be infringed by the generic company's proposed product ("Paragraph IV Certification"). 21 U.S.C. § 355(j)(2)(A)(vii).

20. Pursuant to a Paragraph III or Paragraph IV Certification, the Hatch-Waxman Act allows ANDA applicants to perform all necessary testing, to submit an application for approval, and to receive tentative approval before the relevant patents covering the brand-name pioneer drug expire. Upon the patents' expiration and receipt of FDA final approval, the generic drug companies may market their generic versions of the brand-name drug.

21. If the generic manufacturer submits a Paragraph IV certification, it must notify the patent owner of the filing and explain why the patent is invalid or will not be infringed. 21 U.S.C. § 355(j)(2)(A)(vii)(IV). If the patent holder fails to initiate an infringement suit within forty-five days of receipt of the notice, FDA approval of the ANDA proceeds without regard to patent issues. However, if a patent infringement suit is brought within the forty-five day window, the FDA is automatically barred from approving the ANDA until the earliest of thirty months after the patent holder's receipt of the Paragraph IV certification, the patent expires, or a final judicial determination of non-infringement. 21 U.S.C. § 355(j)(5)(B)(iii).

C. Defendants' Anticompetitive Conduct

Defendants Made Intentional Misrepresentations to the PTO and Engaged in Sham Litigation to Obtain and Maintain an Improper Monopoly for Relafen® and Nabumetone

22. Defendants own the '639 Patent which purported to cover the chemical compound nabumetone. Pursuant to NDA No. 19-583, Defendants marketed Relafen, whose active ingredient is nabumetone, in the United States and elsewhere since February 1992. The '639

Patent resulted from filing of six U.S. patent applications, and ultimately expired on December 13, 2002.

23. Copley Pharmaceutical, Inc. ("Copley"), Teva Pharmaceuticals USA, Inc. ("Teva"), and Eon Labs Manufacturing, Inc. ("Eon") (collectively the "Generic Manufacturers") each manufacture generic pharmaceutical products. Each filed an ANDA with the FDA to market generic versions of Relafen.

24. On August 4, 1997, Copley filed ANDA No. 75-179, the first ANDA for a generic version of the Relafen® 750 mg tablet with a Paragraph IV Certification that the '639 Patent was either invalid or not infringed.

25. On August 18, 1997, Teva filed ANDA No. 75-189, the first ANDA for a generic version of the Relafen® 500 mg tablet with a Paragraph IV Certification that the '639 Patent was either invalid or not infringed. Teva acquired Copley on August 10, 1999, consolidating the ANDAs for both the 500 mg and 750 mg strengths of generic Relafen®.

26. On December 18, 1997, Eon filed ANDA 75-280 for a generic version of the Relafen® 500 mg and 750 mg tablets with a Paragraph IV Certification that the '639 Patent was either invalid or not infringed.

27. The Generic Manufacturers each gave written notice ("notice of certification") to Beecham, pursuant to 21 U.S.C. § 355(j)(2)(B)(i) and (ii), that their ANDAs and the accompanying certification had been filed with the FDA.

28. Defendants sued for infringement of the '639 Patent within forty-five days of the notices of certification (hereinafter referred to collectively as the "Infringement Actions"). Upon filing of the first suit, a 30-month stay of the FDA's authority to grant final marketing approval to the Generic Manufacturers was granted. Final approval could not be given to Teva's and

Copley's ANDAs until either they prevailed in the Infringement Actions, or the 30-month stay expired.

29. The Infringement Actions were consolidated for all purposes and captioned as *In re '639 Patent Litigation*, Civil Action No.97-12416-RCL (D. Mass.) and were assigned to the Honorable Reginald C. Lindsay.

30. The Generic Manufacturers claimed that the '639 Patent was invalid because nabumetone was anticipated by prior art, namely a 1973 article by scientists J.N. Chatterjea and R. Prasad entitled "Condensation of Mannich Base Salts with Phenols: Orientation of Adducts," published in the *Indian Journal of Chemistry*, Volume 11 at 214-18 (March 1973) (the "Chatterjea & Prasad publication"). The Generic Manufacturers argued that the Chatterjea & Prasad publication identified and enabled nabumetone and therefore anticipated all claims set forth in the '639 Patent, either explicitly or inherently. They also claimed that the '639 Patent was unenforceable because Beecham breached its duty of candor to, and engaged in inequitable conduct before, the PTO. *In re '639 Patent Litigation*, 154 F.Supp. 2d 157, 160 (D.Mass. 2001).

31. At all relevant times, Defendants knew that the '639 Patent was not their intellectual development, was anticipated by prior art, and that the '639 Patent was not enforceable because Defendants and their representatives had knowingly made material misrepresentations to the PTO in connection with the prosecution of that patent.

32. Nonetheless, Defendants commenced, prosecuted, and maintained the sham Infringement Actions against the Generic Manufacturers and defended against their counterclaim suits for the improper purpose of maintaining a monopoly in the Relevant Market, and to conceal that unlawful interference and monopoly maintenance.

33. Defendants continued to maintain the sham *Orange Book* listing, the Infringement Actions, and their sham defenses of the counterclaim suits knowingly, intentionally,

affirmatively, with the purpose of unlawfully maintaining their monopoly in the Relevant Market, and with the effect of affirmatively and continuously foreclosing the Generic Manufacturers and any other competitors from the Relevant Market.

34. The FDA granted tentative approval to Eon's ANDA No. 75-280 on August 8, 1998, for nabumetone 500 mg and 750 mg tablets, and to Teva's ANDA No. 75-189 for nabumetone 500 mg and 750 mg tablets on December 24, 1998. This tentative approval reflected the FDA's determination that all the criteria for ANDA "Final" approval had been satisfied, except for the resolution of issues relating to patents or the 180-day exclusivity period. Final approval could not be granted until either the resolution of pending patent infringement litigation or the expiration of the 30-month stay.

35. Final approval was granted on May 26, 2000 to Teva's ANDA No. 75-189 for nabumetone 500 mg tablets, and on June 6, 2000 to Copley's ANDA No. 75-179 for nabumetone 750 mg tablets.

The Court's Ruling Invalidating The '639 Patent

36. On August 14, 2001, Judge Lindsay invalidated the '639 Patent due to prior art and anticipation. The Court also held that the '639 Patent was unenforceable because the Defendants made material misrepresentations to the PTO.

37. The Court then found that the material misrepresentations made by Defendants were made with the intent of deceiving the PTO and entered judgment in favor of the Generic Manufacturers and against SmithKline and Beecham for patent invalidity and unenforceability.

38. Defendants appealed that decision, which was affirmed on August 15, 2002, on the grounds that the patent was invalid because it had been anticipated by prior art. *SmithKline Beecham Corp. v. Copley Pharmaceutical, Inc.*, No. 01-1611, 2002 WL 1890708 (Fed. Cir. Aug.

15, 2002). The Court of Appeals did not reach the issue of inequitable conduct. *Id.* Defendants' post-appeal petitions were denied.

39. Teva began selling a 500 mg generic version of Relafen® on or about August 20, 2001. Teva began selling its 750 mg generic version on or about September 26, 2001.

40. Throughout the course of the proceedings before the PTO and for much of the litigation of the Infringement Actions, Defendants knowingly, willfully and fraudulently concealed the true facts about the Chatterjea & Prasad publication, their knowledge of the existence of prior art, and their misrepresentations to the PTO in order to wrongfully obtain the '639 Patent and to prevent and discourage lawful competition. Thus, Plaintiff States were prevented from discovering the Defendants' illegal conduct.

V. RELEVANT MARKET

41. The relevant product market is the manufacture and sale of nabumetone-based prescription drugs. The relevant geographic market is the United States, including its commonwealths, territories, and protectorates as a whole.

42. The only seller of prescription drugs containing nabumetone in the United States could impose a significant, non-transitory price increase without losing sales sufficient to render the price increase unprofitable, as demonstrated by the Defendants' ability to charge supracompetitive prices for nabumetone during the period in which Relafen® lacked generic competition.

43. A material change in the price of nabumetone relative to that of other NSAIDs would not induce patients to switch. Other NSAIDs are not reasonably considered viable substitutes for Relafen® and generic nabumetone. Each NSAID may cause a variety of side effects, the most common of which are gastrointestinal side effects. Relafen® and generic

nabumetone may produce gastrointestinal and other side effects, but in a manner and extent which are different from, and less severe than, the gastrointestinal side effects of other NSAIDs.

44. Until approximately August 20, 2001, Defendants were the manufacturers and sellers of prescription drugs containing nabumetone in the United States. Their share of the Relevant Market was 100%.

VI. TRADE AND COMMERCE

45. Throughout the relevant period, Relafen® was sold throughout the United States. Relafen® and nabumetone were transported across state lines and sold in each of the Plaintiff States.

46. Defendants' activities, including manufacturing, marketing, distributing and selling Relafen® and nabumetone were in the regular, continuous, and substantial flow of interstate commerce, and have had, and continue to have, a substantial effect upon interstate commerce.

VII. MARKET EFFECTS

47. Defendants' illegal conduct had the purpose or effect of, or the tendency or capacity to, unreasonably restrain and injure competition by preventing the entry of generic nabumetone.

48. Absent Defendants' anticompetitive conduct, at least one generic competitor would have begun marketing a generic version of nabumetone well before August 2001.

49. If a generic competitor had been able to enter the Relevant Market and compete with Defendants, consumers and State Governmental Entities (as payors, purchasers, and reimbursers) would have been free to substitute -- and would have substituted -- a lower-priced generic for the higher-priced brand-name drug.

50. By preventing generic competitors from entering the market, Defendants deprived Plaintiff States and their consumers of the benefits of the competition that the federal and state antitrust laws, consumer protection laws and/or unfair competition statutes and related state laws are designed to promote, preserve, and protect.

VIII. INJURY

51. But for Defendants' anticompetitive acts, consumers and State Governmental Entities would have been able to purchase a generic nabumetone product at a far lower price than the monopoly prices maintained by Defendants, and beginning at an earlier time.

52. As a direct and proximate result of the unlawful conduct alleged above, Plaintiff States, including their State Governmental Entities, were not able to purchase, or pay reimbursements for purchases of, nabumetone products at prices determined by free and open competition, and consequently have been injured in their business and property in that, *inter alia*, they have paid more and continue to pay more for nabumetone products than they would have paid in a free and open competitive market.

53. As a direct and proximate result of the unlawful conduct alleged above, consumers were not able to purchase nabumetone products at prices determined by free and open competition, and consequently have been injured in their business or property in that, *inter alia*, they have paid more and continue to pay more for nabumetone products than they would have paid in a free and open competitive market.

54. As a direct and proximate result of the unlawful conduct alleged above, the general economies of the States have sustained injury, and are threatened with further injury to their business and property unless Defendants are enjoined from their unlawful conduct.

55. As a direct and proximate result of the unlawful conduct alleged above, Defendants have unjustly profited through inflated profit margins and have thus far retained the illegally obtained profits.

X. ALLEGATIONS UNDER FEDERAL LAW

COUNT I

(Violations of Section 2 of the Sherman Act)

56. Plaintiff States repeat each and every preceding allegation as if fully set forth herein.

57. At all relevant times, Defendants maintained monopoly power in the Relevant Market.

58. As described above, Defendants knowingly and willfully engaged in conduct designed to unlawfully obtain and extend their monopoly power in the Relevant Market. These actions included, among others, (i) intentionally submitting false patent information to the FDA; (ii) intentionally submitting fraudulent statements to, and omitting material facts from, the PTO; (iii) prosecuting baseless, sham patent litigation against the Generic Manufacturers; and (iv) maintaining sham defenses to the counterclaims by the Generic Manufacturers.

59. Defendants' Infringement Actions were objectively baseless due to, *inter alia*, the presence of the Chatterjea & Prasad publication, and therefore constituted sham litigation. Further, the purpose of Defendants' notification in bringing the actions was to directly interfere with the ability of the Generic Manufacturers to market less expensive generic versions of Relafen® to compete with the brand-name product.

60. Defendants' illegally created and maintained monopoly power in the Relevant Market in violation of Section 2 of the Sherman Act, 15 U.S.C. § 2.

61. Defendants' conduct in unlawfully obtaining and maintaining a monopoly in the market for Relafen® and nabumetone injured the Plaintiff States in their business or property. Plaintiff States, including their consumers and State Governmental Entities, were deprived of the ability to purchase less expensive, generic versions of Relafen® and paid higher prices for nabumetone-based products than they would have paid, absent Defendants' unlawful conduct.

62. Defendants' anticompetitive and unlawful conduct alleged herein has injured competition in the Relevant Market by obtaining and maintaining their power to exclude competitors, reduce output, charge monopoly prices, reap monopoly profits and otherwise thwart competition in the Relevant Market.

COUNT II **(Unjust Enrichment)**

63. Plaintiff States repeat each and every preceding allegation as if fully set forth herein.

64. As a result of their unlawful conduct described above, Defendants have been and will continue to be unjustly enriched. Defendants' unlawful acts include improperly listing their patent in the *Orange Book*, submitting fraudulent misrepresentations to, and concealing material facts from the PTO; filing and pursuing baseless patent infringement actions; and maintaining baseless defenses to counterclaims at the expense of the Plaintiff States.

65. Defendants' financial benefits from this unlawful and inequitable conduct, including obtaining unlawful overcharges and monopoly profits, were secured to the detriment of and expense of consumers. These benefits are traceable to overpayments for Relafen® by consumers.

66. The overcharges and unlawful monopoly profits derived by Defendants through charging supracompetitive and artificially inflated prices for Relafen® are the direct and proximate result of Defendants' unlawful practices.

67. The financial benefits derived by Defendants rightfully belong in substantial part to the Plaintiff States and consumers.

68. It would be inequitable and unjust for Defendants to be permitted to retain any of the unlawful proceeds resulting from their fraudulent, illegal, and inequitable conduct.

69. Defendants should be compelled to disgorge all unlawful or inequitable proceeds received by them. A constructive trust should be imposed upon all unlawful or inequitable sums received by Defendants traceable to Plaintiff States and consumers.

XI. SUPPLEMENTAL STATE LAW CLAIMS

70. Defendants' conduct described herein constitutes unlawful acts of monopolization and attempts to monopolize, as well as prohibited practices and unconscionable conduct under the antitrust and/or unfair and deceptive trade practices acts of the Plaintiff States, as set forth below.

71. As a result of the conduct described above, Plaintiff States have sustained and will continue to sustain substantial losses and damage to their businesses and property because they were unable to purchase less expensive, generic versions of Relafen, and paid illegally inflated prices for nabumetone products.

72. Plaintiff States seek damages, multiple damages, treble damages, and other damages as permitted by state law, for their injuries caused by these violations pursuant to federal and state law as set forth below. Plaintiff States also seek a declaratory judgment that Defendants' conduct in seeking to prevent competition through the use of the invalid '639 Patent

is unlawful. Plaintiff States further seek equitable and injunctive relief to correct for the anti-competitive market effects and other harms to purchasers caused by the unlawful conduct of Defendants, and other relief so as to assure that similar conduct does not occur in the future.

73. Attorneys General in the Plaintiff States possess sufficient authority to settle and release consumer claims in a *parens patriae* or other representative capacity. Such authority falls into one of the following four categories: (i) *parens patriae* authority expressly conferred by the State legislature, (ii) authority expressly conferred by the State legislature that is the functional equivalent of *parens patriae* authority, (iii) judicially recognized authority to represent consumers, or (iv) authority to proceed as a class representative of consumers pursuant to Fed. R. Civ. P. 23. *F.T.C. v. Mylan Lab.*, 205 F.R.D. 369, 386 - 387 (D.D.C. 2002). In *Mylan*, the Court explicitly recognized these categories of authority.

74. Plaintiff State of Arkansas repeats and realleges each and every allegation contained in paragraphs 1 through 73.

75. Defendants' acts violate, and Plaintiff State of Arkansas is entitled to relief under, the Arkansas Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101 *et seq.* and the Arkansas Unfair Practices Act, Ark. Code Ann. §§ 4-75-201, *et. seq.* 4-75-301, *et. seq.*

76. Plaintiff State of Idaho repeats and realleges each and every allegation contained in paragraphs 1 through 73.

77. Defendants' acts violate, and Plaintiff State of Idaho is entitled to relief under the Idaho Competition Act, Idaho Code §§ 48-101 *et seq.*, and the Idaho Consumer Protection Act, Idaho Code §§ 48-601 *et seq.*

78. Plaintiff State of Illinois repeats and realleges each and every allegation contained in paragraphs 1 through 73.

79. Defendants' acts violate, and Plaintiff State of Illinois is entitled to relief under the Illinois Antitrust Act, 740 ILCS 10/1 *et seq.*, including without limitation 740 ILCS 10/3(3).

80. Plaintiff State of Maryland repeats and realleges each and every allegation contained in paragraphs 1 through 73.

81. Defendants' acts violate, and Plaintiff State of Maryland is entitled to relief under the Maryland Antitrust Act, Md. Com. Law Code Ann. § 11-201, *et seq.* (2000).

82. Plaintiff State of Oregon repeats and realleges each and every allegation contained in paragraphs 1 through 73.

83. Defendants' acts violate, and Plaintiff State of Oregon is entitled to relief under the Oregon Antitrust Act, ORS 646.705, *et seq.*

84. Plaintiff State of Washington repeats and realleges each and every allegation contained in paragraphs 1 through 73.

85. Defendants' acts violate, and Plaintiff State of Washington is entitled to relief under, Wash. Rev. Code 19.86 RCW.

RELIEF REQUESTED

Accordingly, the Plaintiff States demand judgment as follows:

86. Adjudging and decreeing that Defendants engaged in conduct in violation of Section 2 of the Sherman Act, 15 U.S.C. § 2.

87. Adjudging and decreeing that Defendants engaged in conduct in violation of the state statutes and state laws set forth in this Complaint;

88. Enjoining and restraining, pursuant to federal and state law, Defendants, their affiliates, assignees, subsidiaries, successors and transferees, and the officers, directors, partners, agents and employees, and all other persons acting or claiming to act on their behalf or in concert

with them, from engaging in any conduct and from adopting any practice, plan, program or device having a similar purpose or effect to the anticompetitive actions set forth above;

89. Awarding the Plaintiff States all damages sustained on behalf of their consumers, and for all additional damages, penalties and other monetary relief provided by applicable law, including treble damages;

90. Awarding Plaintiff States such other equitable relief, including, but not limited to, restitution and disgorgement, as the Court finds necessary to redress Defendants' violations of federal and state law;

91. Award to each Plaintiff State the maximum civil penalties allowed by law;

92. Granting approval for natural person consumers in Plaintiff States treatment consistent with Group I, as set forth in the proposed settlement currently before this Court in the above captioned case; and

93. Directing such other and further relief as the Court deems just and proper.

JURY TRIAL DEMAND


Plaintiff States demand a trial by jury.

DATED: August 5, 2004

Respectfully submitted,

PLAINTIFF STATES


STATE OF MARYLAND
J. JOSEPH CURRAN, JR.
Attorney General


Meredyth Smith Andrus
Assistant Attorney General
Attorney for the State of Maryland
200 St. Paul Street
Baltimore, Maryland 21202
Telephone: 410-576-6470

FOR PLAINTIFF STATE OF ARKANSAS

MIKE BEEBE
Attorney General of Arkansas

TERESA MARKS
Deputy Attorney General for Public Protection




Bradford Phelps
Assistant Attorney General
Arkansas Bar No. 2001245

Office of the Attorney General
323 Center St.
Little Rock, AR 72201
501/682-3625 (Phone)
501/682-8118 (Facsimile)
Bradford.phelps@ag.state.ar.us


STATE OF IDAHO
LAWRENCE G. WASDEN

Attorney General



Brett T. DeLange
Deputy Attorney General
Consumer Protection Unit
Office of the Attorney General
Attorney for the State of Idaho
Len B. Jordan Building
650 W. State St., Lower Level
P. O. Box 83720
Boise, Idaho 83720-0010
Telephone: 208-334-2424

STATE OF ILLINOIS
LISA MADIGAN
Attorney General




Robert W. Pratt
Chief, Antitrust Bureau
Attorney for the State of Illinois
Office of the Attorney General
100 W. Randolph Street, 13th Floor
Chicago, Illinois 60601
Telephone: 312-814-3722

STATE OF OREGON
HARDY MYERS
Attorney General



Michelle Teed
Assistant Attorney General
Attorney for the State of Oregon
Oregon Department of Justice
1162 Court Street NE
Salem, Oregon 97301
Telephone: 503-947-4333

STATE OF WASHINGTON
CHRISTINE O. GREGOIRE
Attorney General


Tina E. Kondo

Senior Assistant Attorney General
Antitrust Division Chief
Antitrust Division
Attorney for the State of Washington
900 Fourth Avenue, Suite 2000
Seattle, Washington 98164
Telephone: (206) 464-7589

JS 44 (Rev. 3/99)

CIVIL COVER SHEET

The JS-44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON THE REVERSE OF THE FORM.)

I. (a) PLAINTIFFS

States of Maryland, Arkansas, Idaho, Illinois
Oregon and Washington

(b) County of Residence of First Listed Plaintiff Baltimore
(EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorney's (Firm Name, Address, and Telephone Number)

State Attorneys' General Offices -
see attached

DEFENDANTS

SmithKline Beecham Corp. and
SmithKline Beecham plc

County of Residence of First Listed Philadelphia
(IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE
LAND INVOLVED.

Attorneys (If Known)

See attached
04 11726 WGY

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- ☐ 1 U.S. Government Plaintiff
☐ 2 U.S. Government Defendant
☒ 3 Federal Question (U.S. Government Not a Party)
☐ 4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

- Citizen of This State ☐ 1 ☐ 1 Incorporated or Principal Place of Business in This State ☐ 4 ☐ 4
Citizen of Another State ☐ 2 ☐ 2 Incorporated and Principal Place of Business in Another State ☐ 5 ☐ 5
Citizen or Subject of a Foreign Country ☐ 3 ☐ 3 Foreign Nation ☐ 6 ☐ 6

IV. NATURE OF SUIT (Place an "X" in One Box Only)

CONTRACT	TORTS	FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES
<input type="checkbox"/> 110 Insurance <input type="checkbox"/> 120 Marine <input type="checkbox"/> 130 Miller Act <input type="checkbox"/> 140 Negotiable Instrument <input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Federal Tax Act <input type="checkbox"/> 152 Recovery of Defaulted Student Loans (Excl. Veterans) <input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits <input type="checkbox"/> 160 Stockholders' Suits <input type="checkbox"/> 190 Other Contract <input type="checkbox"/> 195 Contract Product Liability	PERSONAL INJURY <input type="checkbox"/> 310 Airplane <input type="checkbox"/> 315 Airplane Product Liability <input type="checkbox"/> 320 Assault, Libel & Slander <input type="checkbox"/> 330 Federal Employers' Liability <input type="checkbox"/> 340 Marine <input type="checkbox"/> 345 Marine Product Liability <input type="checkbox"/> 350 Motor Vehicle <input type="checkbox"/> 355 Motor Vehicle Product Liability <input type="checkbox"/> 360 Other Personal Injury	<input type="checkbox"/> 610 Agriculture <input type="checkbox"/> 620 Other Food & Drug <input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC <input type="checkbox"/> 630 Liquor Laws <input type="checkbox"/> 640 R.R. & Truck <input type="checkbox"/> 650 Airline Regs. <input type="checkbox"/> 660 Occupational Safety/Health <input type="checkbox"/> 690 Other	<input type="checkbox"/> 422 Appeal 28 USC 158 <input type="checkbox"/> 423 Withdrawal 28 USC 157 PROPERTY RIGHTS <input type="checkbox"/> 820 Copyrights <input type="checkbox"/> 830 Patent <input type="checkbox"/> 840 Trademark SOCIAL SECURITY <input type="checkbox"/> 861 HTA (13 USC) <input type="checkbox"/> 862 Black Lung (923) <input type="checkbox"/> 863 DIW C/DIWW (405 (g)) <input type="checkbox"/> 864 SSD Title XVI <input type="checkbox"/> 865 RST (405(g))	<input type="checkbox"/> 400 State Reapportionment <input checked="" type="checkbox"/> 410 Antitrust <input type="checkbox"/> 430 Banks and Banking <input type="checkbox"/> 450 Commerce/ICC Rates/etc. <input type="checkbox"/> 460 Deportation <input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations <input type="checkbox"/> 810 Selective Service <input type="checkbox"/> 850 Securities/Commodities/Exchange <input type="checkbox"/> 875 Customer Challenge 12 USC 3410 <input type="checkbox"/> 891 Agricultural Acts <input type="checkbox"/> 892 Economic Stabilization Act <input type="checkbox"/> 893 Environmental Matters <input type="checkbox"/> 894 Energy Allocation Act <input type="checkbox"/> 895 Freedom of Information Act <input type="checkbox"/> 900 Appeal of Fee Determination Equal Access to Justice <input type="checkbox"/> 950 Constitutionality of State Statutes <input type="checkbox"/> 890 Other Statutory Actions
REAL PROPERTY	CIVIL RIGHTS	PRISONER PETITIONS	FEDERAL TAX SUITS	
<input type="checkbox"/> 210 Land Condemnation <input type="checkbox"/> 220 Foreclosure <input type="checkbox"/> 230 Rent Lease & Ejectment <input type="checkbox"/> 240 Torts to Land <input type="checkbox"/> 245 Tort Product Liability <input type="checkbox"/> 290 All Other Real Property	<input type="checkbox"/> 441 Voting <input type="checkbox"/> 442 Employment <input type="checkbox"/> 443 Housing/Accommodations <input type="checkbox"/> 444 Welfare <input type="checkbox"/> 440 Other Civil Rights	<input type="checkbox"/> 510 Motions to Vacate Sentence <input type="checkbox"/> Habeas Corpus: <input type="checkbox"/> 530 General <input type="checkbox"/> 535 Death Penalty <input type="checkbox"/> 540 Mandamus & Other <input type="checkbox"/> 550 Civil Rights <input type="checkbox"/> 555 Prison Condition	<input type="checkbox"/> 710 Fair Labor Standards Act <input type="checkbox"/> 720 Labor/Mgmt. Relations <input type="checkbox"/> 730 Labor/Mgmt. Reporting & Disclosure Act <input type="checkbox"/> 740 Railway Labor Act <input type="checkbox"/> 790 Other Labor Litigation <input type="checkbox"/> 791 Empl. Ret. Inc. Security Act <input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant) <input type="checkbox"/> 871 IRS—Third Party 26 USC 7609	

V. ORIGIN

(PLACE AN "X" IN ONE BOX ONLY)

- ☒ 1 Original Proceeding
☐ 2 Removed from State Court
☐ 3 Remanded from Appellate Court
☐ 4 Reinstated or Reopened
☐ 5 Transferred from another district (specify)
☐ 6 Multidistrict Litigation
☐ 7 Appeal to District Judge from Magistrate Judgment

VI. CAUSE OF ACTION

(Cite the U.S. Civil Statute under which you are filing and write brief statement of cause. Do not cite jurisdictional statutes unless diversity.)

15 U.S.C. § 2 - Monopolization, attempted monopolization, unjust enrichment.

VII. REQUESTED IN COMPLAINT:

☐ CHECK IF THIS IS A CLASS ACTION UNDER F.R.C.P. 23

DEMAND \$

CHECK YES only if demanded in complaint:

JURY DEMAND: ☒ YES ☐ NO

VIII. RELATED CASE(S)

(See instructions):

IF ANY

JUDGE
B

Young

see attached;
DOCKET NUMBER 01-CV-12239-WGV

DATE 8-3-04 SIGNATURE OF ATTORNEY OF RECORD

FOR OFFICE USE ONLY

RECEIPT # AMOUNT APPLYING IF JUDGE MAG. JUDGE

UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTSFILED
IN CLERK'S OFFICE1. Title of case (name of first party on each side only) State of Maryland vs.
SmithKline Beecham Corp.

2. Category in which the case belongs based upon the numbered nature of suit code listed on the civil cover sheet. (See local rule 40.1(a)(1)).

- ☒ I. 160, 410, 470, R.23, REGARDLESS OF NATURE OF SUIT.
- ☐ II. 195, 368, 400, 440, 441-444, 540, 550, 555, 625, 710, 720, 730, 740, 790, 791, 820*, 830*, 840*, 850, 890, 892-894, 895, 950. *Also complete AO 120 or AO 121 for patent, trademark or copyright cases
- ☐ III. 110, 120, 130, 140, 151, 190, 210, 230, 240, 245, 290, 310, 315, 320, 330, 340, 345, 350, 355, 360, 362, 365, 370, 371, 380, 385, 450, 891.
- ☐ IV. 220, 422, 423, 430, 460, 510, 530, 610, 620, 630, 640, 650, 660, 690, 810, 861-865, 870, 871, 875, 900.
- ☐ V. 150, 152, 153.

04 11726 WGY

3. Title and number, if any, of related cases. (See local rule 40.1(g)). If more than one prior related case has been filed in this district please indicate the title and number of the first filed case in this court.

01-CV-12239-WGY (See also attached list)

4. Has a prior action between the same parties and based on the same claim ever been filed in this court?

See Motions to Intervene

YES ☐ NO ☒

5. Does the complaint in this case question the constitutionality of an act of congress affecting the public interest? (See 28 USC §2403)

YES ☐ NO ☒

If so, is the U.S.A. or an officer, agent or employee of the U.S. a party?

N/A

YES ☐ NO ☐

6. Is this case required to be heard and determined by a district court of three judges pursuant to title 28 USC §2284?

YES ☐ NO ☒

7. Do all of the parties in this action, excluding governmental agencies of the united states and the Commonwealth of Massachusetts ("governmental agencies"), residing in Massachusetts reside in the same division? - (See Local Rule 40.1(d)).

YES ☐ NO ☒

A. If yes, in which division do all of the non-governmental parties reside?

Eastern Division ☐ Central Division ☐ Western Division ☐

B. If no, in which division do the majority of the plaintiffs or the only parties, excluding governmental agencies, residing in Massachusetts reside? N/A

Eastern Division ☐ Central Division ☐ Western Division ☐

8. If filing a Notice of Removal - are there any motions pending in the state court requiring the attention of this Court? (If yes, submit a separate sheet identifying the motions)

N/A

YES ☐ NO ☐

(PLEASE TYPE OR PRINT)

ATTORNEY'S NAME Meredyth AndrusADDRESS 200 St. Paul Place, 19th Floor Baltimore, MD 21202-2021TELEPHONE NO. 410-576-6470

SUPPLEMENTS
CIVIL COVER SHEET SEC. I

PLAINTIFF STATES

STATE OF MARYLAND
J. JOSEPH CURRAN, JR.
Attorney General

Meredyth Smith Andrus
Assistant Attorney General
Attorney for the State of Maryland
200 St. Paul Street
Baltimore, Maryland 21202
Telephone: 410-576-6470

04 11726 WCY

STATE OF ARKANSAS
MIKE BEEBE
Attorney General of Arkansas

Bradford J. Phelps
Assistant Attorney General
Attorney for the State of Arkansas
323 Center Street, Suite 200
Little Rock, Arkansas 72201
Telephone: 501-682-3625

STATE OF IDAHO
LAWRENCE G. WASDEN
Attorney General

Brett T. DeLange
Deputy Attorney General
Consumer Protection Unit
Office of the Attorney General
Attorney for the State of Idaho
Len B. Jordan Building
650 W. State St., Lower Level
P. O. Box 83720
Boise, Idaho 83720-0010
Telephone: 208-334-2424

STATE OF ILLINOIS
LISA MADIGAN
Attorney General

Robert W. Pratt
Chief, Antitrust Bureau
Attorney for the State of Illinois
Office of the Attorney General
100 W. Randolph Street, 13th Floor
Chicago, Illinois 60601
Telephone: 312-814-3722

STATE OF OREGON
HARDY MYERS
Attorney General

Michelle Teed
Assistant Attorney General
Attorney for the State of Oregon
Oregon Department of Justice
1162 Court Street NE
Salem, Oregon 97301
Telephone: 503-947-4333

STATE OF WASHINGTON
CHRISTINE O. GREGOIRE
Attorney General

Tina B. Kondo
Senior Assistant Attorney General
Antitrust Division Chief
Antitrust Division
Attorney for the State of Washington
900 Fourth Avenue, Suite 2000
Seattle, Washington 98164
Telephone: (206) 464-7589

04 11726 WCY

Supplements Local Cover Sheet - Related Cases

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

IN RE RELAFEN ANTITRUST LITIGATION

THIS DOCUMENT RELATES TO END- PAYOR ACTIONS:

Lynch v. SmithKline Beecham Corp.

*A.F. of L.- AGC Building Trades Welfare
Plan v. SmithKline Beecham Corp.*

*Twin Cities Bakery Workers Health & Welfare
Fund v. SmithKline Beecham Corp.*

Houchins v. SmithKline Beecham Corp.

*Teamsters Local No. 35 Health Plans v.
SmithKline Beecham Corp.*

*Smithfield Foods, Inc. v. SmithKline
Beecham Corp.*

Franklin v. SmithKline Beecham Corp.

Fox v. SmithKline Beecham Corp.

Kravitz v. SmithKline Beecham Corp.

Master File
No. 01-CV-12239-WGY

No. 02-CV-10163-WGY

No. 02-CV-10205-WGY

No. 02-CV-985 (E.D. Pa.)

No. 02-CV-10424-WGY

No. 02-CV-10487-WGY

No. 02-CV-10589-WGY

No. 02-CV-10671-WGY

No. 02-CV-11543-WGY

No. 02-CV-11806-WGY

**Supplements
CIVIL COVER SHEET Sec. I**

1:01-cv-12239-WGY Meijer, Inc., et al v. Smithkline Beecham, et al

William G. Young, presiding

Date filed: 12/18/2001

Date terminated: 04/13/2004 Date of last filing: 07/30/2004

Attorneys

04 11726 WGY

William Alper

Cohen, Pontani, Lieberman & Pavane
551 Fifth Avenue
Suite 1210
New York, NY 10176
212-687-2770

Assigned: 05/09/2003

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

representing

Eon Labs, Inc.

(Consolidated Plaintiff)

Meredyth Smith Andrus

Office of the Maryland Attorney General
200 St. Paul Place
Baltimore, MD 21202
410-576-6477

410-576-7830 (fax)

mandrus@oag.state.md.us

Assigned: 07/26/2004

ATTORNEY TO BE NOTICED

representing

State of Maryland

(Intervenor Plaintiff)

Richard Alan Arnold

Kenny Nachwalter, PA
Suite 1100
201 South Biscayne Blvd.
Miami, FL 33131

305-373-1000

305-372-1861 (fax)

sscott@knsacs.com

Assigned: 05/09/2003

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

representing

Walgreen Company

(Consolidated Plaintiff)

Michael J. Boni

Kohn, Swift & Graf
One South Broad Street
Ste. 2100

Philadelphia, PA 19107

215-238-1700

Assigned: 01/28/2003

representing

Meijer Distribution, Inc.

(Plaintiff)

ATTORNEY TO BE NOTICED

Bernard J. Bonn, III
Abbey Gardy & Squitieri
212 East 39th Street
New York, NY 10016
617-728-7143
617-426-6567 (fax)
bernard.bonn@dechert.com
Assigned: 01/11/2002
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Meijer, Inc.
(Plaintiff)

Direct Purchaser
(Consolidated Plaintiff)

Glaxosmithkline PLC
(Defendant)

**Smithkline Beecham
Corporation**
(Defendant)

Jacqueline E. Bryks
Cohen, Milstein, Hausfeld & Toll
825 Third Ave., 30th Floor
New York, NY 10022
212-838-7797
Assigned: 06/06/2002
ATTORNEY TO BE NOTICED

representing

Meijer Distribution, Inc.
(Plaintiff)

Meijer, Inc.
(Plaintiff)

Michael M. Buchman
Milberg, Weiss, Bershad & Schulman LLP
One Pennsylvania Plaza
New York, NY 10119-0165
212-594-5300
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**A.F. of L. - A.G.C. Building
Trades Welfare Plan**
(Consolidated Plaintiff)

End-Payor Plaintiffs
(Consolidated Plaintiff)

Hy-Vee, Inc.
(Consolidated Plaintiff)

IBEW - NECA Local 505
Health & Welfare Plan
(Consolidated Plaintiff)

Sheet Metal Workers Local
441 Health & Welfare Plan
(Consolidated Plaintiff)

Patrick E. Cafferty
Miller, Faucher and Cafferty, LLP
101 N. Main Street
Suite 885
Ann Arbor, MI 48104
734-769-2144
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

A.F. of L. - A.G.C. Building
Trades Welfare Plan
(Consolidated Plaintiff)

End-Payor Plaintiffs
(Consolidated Plaintiff)

Hy-Vee, Inc.
(Consolidated Plaintiff)

IBEW - NECA Local 505
Health & Welfare Plan
(Consolidated Plaintiff)

Safeway, Inc.
(Consolidated Plaintiff)

Sheet Metal Workers Local
441 Health & Welfare Plan
(Consolidated Plaintiff)

Neill Clark

Berger & Montague
1622 Locust Street
Philadelphia, PA 19107
215-875-3000

Assigned: 05/07/2003

ATTORNEY TO BE NOTICED

representing

Meijer Distribution, Inc.
(Plaintiff)

Meijer, Inc.
(Plaintiff)

Eric Cramer

Berger & Montague
1622 Locust Street
Philadelphia, PA 19107
215-875-3000

Assigned: 05/07/2003

ATTORNEY TO BE NOTICED

representing

Meijer Distribution, Inc.
(Plaintiff)

Meijer, Inc.
(Plaintiff)

Brett T. DeLange

Idaho Attorney General's Office
Consumer Protection Unit
Len B. Jordan Building
650 W. State Street
Boise, ID 83720-0010
208-334-4114
208-334-2830 (fax)
bdelange@ag.state.id.us

Assigned: 07/26/2004

ATTORNEY TO BE NOTICED

representing

State of Idaho
(Intervenor Plaintiff)

Glen DeValerio

Berman DeValerio Pease Tabacco Burt &
Pucillo
One Liberty Square
8th Floor
Boston, MA 02109
617-542-8300
617-542-1194 (fax)
gdevalerio@bermanesq.com

Assigned: 05/09/2003

LEAD ATTORNEY

representing

Smithfield Foods, Inc
(Consolidated Plaintiff)

ATTORNEY TO BE NOTICED

Louise Houchins
(Consolidated Plaintiff)

Kathleen M. Donovan-Maher
Berman DeValerio Pease Tabacco Burt &
Pucillo
One Liberty Square
8th Floor
Boston, MA 02109
617/542-8300
617/542-1194 (fax)
kdonovanmaher@bermanesq.com
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Louise Houchins
(Consolidated Plaintiff)

Ruth T. Dowling
Palmer & Dodge, LLP
111 Huntington Avenue
Boston, MA 02199
617-239-0657
617-227-4420 (fax)
rdowling@palmerdodge.com
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Eon Labs, Inc.
(Consolidated Plaintiff)

Nancy F. Gans
Moulton & Gans, PC
33 Broad Street
Suite 1100
Boston, MA 02109
617-369-7979
617-369-7980 (fax)
nfgans@aol.com
Assigned: 06/23/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Meijer Distribution, Inc.
(Plaintiff)

Meijer, Inc.
(Plaintiff)

George G. Gordon
Dechert LLP
4000 Bell Atlantic Tower
1717 Arch Street
Philadelphia, PA 19103-2793
Assigned: 05/17/2002
ATTORNEY TO BE NOTICED

representing

Glaxosmithkline PLC
(Defendant)

**Smithkline Beecham
Corporation**
(Defendant)

Daniel E. Gustafson
Heins Mills & Olson, P.L.C.
3550 IDS Center
80 South Eighth Street
Minneapolis, MN 55402
612-338-4605
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**A.F. of L. - A.G.C. Building
Trades Welfare Plan**
(Consolidated Plaintiff)

End-Payor Plaintiffs
(Consolidated Plaintiff)

Hy-Vee, Inc.
(Consolidated Plaintiff)

**IBEW - NECA Local 505
Health & Welfare Plan**
(Consolidated Plaintiff)

**Sheet Metal Workers Local
441 Health & Welfare Plan**
(Consolidated Plaintiff)

Richard C. Heidlage
Attorney General's Office
200 Portland Street
Boston, MA 02114
617-727-2200
617-727-2008 (fax)
richard.heidlage@ago.state.ma.us

representing

State of Arkansas
(Intervenor Plaintiff)

Assigned: 07/07/2004

ATTORNEY TO BE NOTICED

State of Idaho

(Intervenor Plaintiff)

State of Illinois

(Intervenor Plaintiff)

State of Maryland

(Intervenor Plaintiff)

State of Oregon

(Intervenor Plaintiff)

State of Washington

(Intervenor Plaintiff)

Samuel D. Heins

Heins Mills & Olson, P.L.C.

3550 IDS Center

80 South Eighth Street

Minneapolis, MN 55402

612-338-4605

Assigned: 05/09/2003

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

representing

A.F. of L. - A.G.C. Building

Trades Welfare Plan

(Consolidated Plaintiff)

End-Payor Plaintiffs

(Consolidated Plaintiff)

Hy-Vee, Inc.

(Consolidated Plaintiff)

IBEW - NECA Local 505

Health & Welfare Plan

(Consolidated Plaintiff)

Sheet Metal Workers Local

441 Health & Welfare Plan

(Consolidated Plaintiff)

Theodore M. Hess-Mahan
Shapiro Haber & Urmey LLP
53 State Street
Boston, MA 02108
617-439-3939
617-439-0134 (fax)
ted@shulaw.com
Assigned: 05/07/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Direct Purchaser
(Consolidated Plaintiff)

Elliot Franklin
(Consolidated Plaintiff)

Timothy C. Hester
Covington & Burling
1201 Pennsylvania Avenue, N.W.
P.O. Box 7566
Washington, DC 20044
202-662-6000
Assigned: 05/17/2002
ATTORNEY TO BE NOTICED

representing

Glaxosmithkline PLC
(Defendant)

**Smithkline Beecham
Corporation**
(Defendant)

Beecham Group PLC
(Consolidated Defendant)

Elizabeth J. Holland
Kenyon & Kenyon
One Broadway
New York, NY 10004
212-425-7200
Assigned: 05/07/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**Teva Pharmaceutical
Industries LTD**
(Consolidated Plaintiff)

**Teva Pharmaceuticals USA,
Inc.**
(Consolidated Plaintiff)

Mayme A. Holt-Brown
Percy, Smith, Foote, & Gadel, LLP
720 Murray Street
Alexandria, LA 71309-1632
318-445-4480

Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**Teamsters Local No. 35 Heath
Plans**
(Consolidated Plaintiff)

Elliot Franklin
(Consolidated Plaintiff)

Patrick J. Lynch
(Consolidated Plaintiff)

Donivan Irby
Office of Attorney General of Washington
900 4th Avenue
Suite 2000
Seattle, WA 98164-1012
206-464-7589
206-587-5636 (fax)

Assigned: 07/26/2004
ATTORNEY TO BE NOTICED

representing

State of Washington
(Intervenor Plaintiff)

Michael J. Kane
MAGER WHITE & GOLDSTEIN LLP
One Pitcairn Place
Suite 2400
165 Township Line Road
Jenkintown, PA 19046
215-481-0273

Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Barbara Brown
(Consolidated Plaintiff)

Robert N. Kaplan
Kaplan, Fox & Kilsheimer LLP
805 Third Avenue
22nd Floor
New York, NY 10022
212-687-1980

Assigned: 03/04/2003
ATTORNEY TO BE NOTICED

representing

Meijer Distribution, Inc.
(Plaintiff)

Kevin T. Kerns
Dechert LLP
4000 Bell Atlantic Tower
1717 Arch Street
Philadelphia, PA 19103-2793
Assigned: 05/17/2002
ATTORNEY TO BE NOTICED

representing

Meijer, Inc.
(Plaintiff)

Glaxosmithkline PLC
(Defendant)

**Smithkline Beecham
Corporation**
(Defendant)

Richard J. Kilsheimer
Kaplan Fox & Kilsheimer LLP
805 Third Avenue
22nd Floor
New York, NY 10022
212-687-1980
Assigned: 03/14/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Meijer Distribution, Inc.
(Plaintiff)

Meijer, Inc.
(Plaintiff)

Peter Kohn
Berger & Montague
1622 Locust Street
Philadelphia, PA 19107
215-875-3000
Assigned: 05/07/2003
ATTORNEY TO BE NOTICED

representing

Meijer Distribution, Inc.
(Plaintiff)

Meijer, Inc.
(Plaintiff)

Steven J. Lee
Kenyon & Kenyon
One Broadway
New York, NY 10004

representing

**Teva Pharmaceutical
Industries LTD**

212-425-7200
Assigned: 05/07/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

(Consolidated Plaintiff)

**Teva Pharmaceuticals USA,
Inc.**
(Consolidated Plaintiff)

Theodore M. Leiverman
Spector, Roseman & Kodroff
1818 Market Street
2500
Philadelphia, PA 19103
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**A.F. of L. - A.G.C. Building
Trades Welfare Plan**
(Consolidated Plaintiff)

End-Payor Plaintiffs
(Consolidated Plaintiff)

**IBEW - NECA Local 505
Health & Welfare Plan**
(Consolidated Plaintiff)

**Sheet Metal Workers Local
441 Health & Welfare Plan**
(Consolidated Plaintiff)

Lester L. Levy
Wolf, popper, Ross, Wolf & Jones
845 Third Avenue
New York, NY 10022
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Barbara Brown
(Consolidated Plaintiff)

Richard D Margiano
Cohen, Pontani, Lieberman and Pavane
551 5th Avenue
New York, NY 10176
Assigned: 06/05/2003
ATTORNEY TO BE NOTICED

representing

Eon Labs, Inc.
(Consolidated Plaintiff)

James W. Matthews
Sherin and Lodgen LLP
101 Federal Street
Boston, MA 02110
617-646-2000
617-646-2222 (fax)
jwmattthews@sherin.com
Assigned: 05/07/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**Teva Pharmaceutical
Industries LTD**
(Consolidated Plaintiff)

**Teva Pharmaceuticals USA,
Inc.**
(Consolidated Plaintiff)

CVS Meridian, Inc.
(Consolidated Plaintiff)

Rite Aid Corp.
(Consolidated Plaintiff)

Robert J. Muldoon, Jr.
Sherin & Lodgen LLP
101 Federal Street
Boston, MA 02110-2104
617-646-2000
617-646-2222 (fax)
rjmuldoon@sherin.com
Assigned: 05/07/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**Teva Pharmaceutical
Industries LTD**
(Consolidated Plaintiff)

**Teva Pharmaceuticals USA,
Inc.**
(Consolidated Plaintiff)

CVS Meridian, Inc.
(Consolidated Plaintiff)

Rite Aid Corp.
(Consolidated Plaintiff)

Jonathan D. Mutch

Robins, Kaplan, Miller & Ciresi L.L.P.
111 Huntington Avenue
Boston, MA 02119
617-267-2300
617-267-8288 (fax)
jdmutch@rkmc.com
Assigned: 05/14/2004
ATTORNEY TO BE NOTICED

representing

Insurer Group
(Plaintiff)

End-Payor Plaintiffs
(Consolidated Plaintiff)

Dianne M. Nast
Roda & Nast, P.C.
801 Estelle Drive
Lancaster, PA 17601
Assigned: 02/19/2004
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

SAJ Distributors, Inc.
(Interested Party)

Stephen L. LaFrance
Holdings, Inc.
(Interested Party)

Edward Notargiacomo
Hagens Berman LLP
One Main Street
4th Floor
Cambridge, MA 02141
617-482-3700
617-374-3003 (fax)
ed@hagens-berman.com
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

A.F. of L. - A.G.C. Building
Trades Welfare Plan
(Consolidated Plaintiff)

End-Payor Plaintiffs
(Consolidated Plaintiff)

Hy-Vee, Inc.
(Consolidated Plaintiff)

IBEW - NECA Local 505

Health & Welfare Plan
(Consolidated Plaintiff)

Safeway, Inc.
(Consolidated Plaintiff)

**Sheet Metal Workers Local
441 Health & Welfare Plan**
(Consolidated Plaintiff)

Barbara Brown
(Consolidated Plaintiff)

Jennifer Kravitz
(Consolidated Plaintiff)

Linda P. Nussbaum
Cohen, Milstein, Hausfeld & Toll
825 Third Ave., 30th Floor
New York, NY 10022
212-838-7797
Assigned: 06/06/2002
ATTORNEY TO BE NOTICED

representing

Meijer Distribution, Inc.
(Plaintiff)

Meijer, Inc.
(Plaintiff)

Joseph Oppen
Garwin, Bronzaft, Gerstein & Fisher
1501 Broadway
New York, NY 01002
212-391-0055
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**Teva Pharmaceutical
Industries LTD**
(Consolidated Plaintiff)

**Teva Pharmaceuticals USA,
Inc.**
(Consolidated Plaintiff)

Margaret H. Paget
Sherin & Lodgen

101 Federal Street
Boston, MA 02110
617-646-2000
617-646-2222 (fax)
mhpaget@sherin.com
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**Teva Pharmaceutical
Industries LTD**
(Consolidated Plaintiff)

**Teva Pharmaceuticals USA,
Inc.**
(Consolidated Plaintiff)

David K. Park
Willkie Farr & Gallagher
787 Seventh Avenue
New York, NY 10019
212-728-8000
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**Teva Pharmaceutical
Industries LTD**
(Consolidated Plaintiff)

**Teva Pharmaceuticals USA,
Inc.**
(Consolidated Plaintiff)

David Pastor
Gilman and Pastor, LLP
Stonehill Corporate Center
999 Broadway, Suite 500
Saugus, MA 01906
781-231-7850
781-231-7840 (fax)
dpastor@gilmanpastor.com
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Tyler Fox
(Consolidated Plaintiff)

Douglas H. Patton
Dewsnup, King & Olsen
Beneficial Life Tower
36 South State Street
Suite 2020
Salt Lake City, UT 84111
801-533-0400

representing

**Teamsters Local No. 35 Heath
Plans**
(Consolidated Plaintiff)

Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Walgreen Company
(Consolidated Plaintiff)

Elliot Franklin
(Consolidated Plaintiff)

Patrick J. Lynch
(Consolidated Plaintiff)

CVS Meridian, Inc.
(Consolidated Plaintiff)

Direct Purchaser
(Consolidated Plaintiff)

Bernard Persky
Goodkind, Labaton, Rudoff & Sucharow,
LLP
100 Park Avenue
New York, NY 10017
212-907-0700

Assigned: 02/03/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Meijer Distribution, Inc.
(Plaintiff)

Scott E. Perwin
Kenny, Nachwalter, Seymour, Arnold,
Critchlow & Spector
1100 Miami Center
201 South Biscayne Boulevard
Miami, FL 33131
305-373-1000
305-372-1861 (fax)
mmitchell@knsacs.com

Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Albertson's, Inc.
(Consolidated Plaintiff)

Eckerd Corporation

(Consolidated Plaintiff)

Hy-Vee, Inc.
(Consolidated Plaintiff)

Kroger Co., The
(Consolidated Plaintiff)

Walgreen Company
(Consolidated Plaintiff)

Bradford J. Phelps
Office of the Attorney General of Arkansas
323 Center Street
Suite 200
Little Rock, AR 72201
501-682-3625
Assigned: 07/26/2004
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

State of Arkansas
(Intervenor Plaintiff)

Matthew A. Porter
Dechert LLP
200 Clarendon Street
27th Floor
Boston, MA 02116
617-728-7100
617-426-6567 (fax)
matthew.porter@dechert.com
Assigned: 02/15/2002
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Glaxosmithkline PLC
(Defendant)

**Smithkline Beecham
Corporation**
(Defendant)

Carl J. Rose
(Consolidated Defendant)

Richard K. Anderson
(Consolidated Defendant)

Robert Pratt

Office of the Illinois Attorney General
Antitrust Bureau

100 W. Randolph Street, 13th Floor
Chicago, IL 60601

312-814-3722

312-814-1154 (fax)

Assigned: 07/26/2004

ATTORNEY TO BE NOTICED

representing

State of Illinois

(Intervenor Plaintiff)

Barry L. Refsin

Hangley, Aronhick, Segal & Pudlin
One Logan Square

27th Floor

Philadelphia, PA 19103-6933

215-496-7031

215-568-0300 (fax)

brefsin@hangley.com

Assigned: 05/09/2003

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

representing

CVS Meridian, Inc.

(Consolidated Plaintiff)

J. Douglas Richards

Milberg, Weiss, Berhsad & Schulman LLP

One Pennsylvania Plaza

New York, NY 10119-0165

212-594-5300

Assigned: 05/09/2003

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

representing

A.F. of L. - A.G.C. Building

Trades Welfare Plan

(Consolidated Plaintiff)

End-Payor Plaintiffs

(Consolidated Plaintiff)

Hy-Vee, Inc.

(Consolidated Plaintiff)

IBEW - NECA Local 505

Health & Welfare Plan

(Consolidated Plaintiff)

Sheet Metal Workers Local

441 Health & Welfare Plan

(Consolidated Plaintiff)

William H. Rooney
Willkie Farr & Gallagher
787 Seventh Avenue
New York, NY 10019
212-728-8000

Assigned: 05/07/2003

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

representing

**Teva Pharmaceutical
Industries LTD**
(Consolidated Plaintiff)

**Teva Pharmaceuticals USA,
Inc.**
(Consolidated Plaintiff)

Hollis L. Salzman
Goodkind, Labaton, Rudoff & Sucharow,
LLP
100 Park Avenue
New York, NY 10017
212-907-0700

Assigned: 02/03/2003

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

representing

Meijer Distribution, Inc.
(Plaintiff)

L. Kendall Satterfield
Finkelstein, Thompson & Loughran
1050 30th Street, N.W.
Washington, DC 20007
202-337-8000
202-337-8090 (fax)

Assigned: 12/01/2003

ATTORNEY TO BE NOTICED

representing

Direct Purchaser
(Consolidated Plaintiff)

Stephen H. Schwartz
Garwin, Bronzaft, Gerstein & Fisher
1501 Broadway
New York, NY 01002
212-391-0055

Assigned: 05/07/2003

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

representing

Direct Purchaser
(Consolidated Plaintiff)

**Teva Pharmaceutical
Industries LTD**
(Consolidated Plaintiff)

**Teva Pharmaceuticals USA,
Inc.**
(Consolidated Plaintiff)

Thane D. Scott
Palmer & Dodge, LLP
111 Huntington Avenue
Prudential Center
Boston, MA 02199
617-239-0100
617-227-4420 (fax)
tscott@palmerdodge.com
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Eon Labs, Inc.
(Consolidated Plaintiff)

Steve D. Shadowen
Hangley, Aronchick, Segal & Pudlin
30 North Third Street
Suite 700
Harrisburg, PA 17101-1701
717-364-1010
717-364-1020 (fax)
sshadowen@hangley.com
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

CVS Meridian, Inc.
(Consolidated Plaintiff)

Jay B. Shapiro
Stearns, Weaver, Miller, Weissler, Alhadeff
& Sitterson, P.C.
Museum Tower, Suite 2200
150 West Flagler Street, FL 33130
305-789-3200
Assigned: 08/07/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Direct Purchaser
(Consolidated Plaintiff)

Thomas G. Shapiro
Shapiro Haber & Urmey LLP
53 State Street
Boston, MA 02108
617-439-3939
617-439-0134 (fax)
tshapiro@shulaw.com
Assigned: 12/18/2001

representing

Meijer Distribution, Inc.
(Plaintiff)

LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Meijer, Inc.
(Plaintiff)

Direct Purchaser
(Consolidated Plaintiff)

**Teamsters Local No. 35 Heath
Plans**
(Consolidated Plaintiff)

Elliot Franklin
(Consolidated Plaintiff)

Patrick J. Lynch
(Consolidated Plaintiff)

Christopher N. Sipes
Covington & Burling
1201 Pennsylvania Avenue, N.W.
P.O. Box 7566
Washington, DC 20044
202-662-6000
Assigned: 05/17/2002
ATTORNEY TO BE NOTICED

representing

Glaxosmithkline PLC
(Defendant)

**Smithkline Beecham
Corporation**
(Defendant)

Beecham Group PLC
(Consolidated Defendant)

David P. Smith
Percy, Smith, Foote, & Gadel, LLP
720 Murray Street
Alexandria, LA 71309-1632
318-445-4480
Assigned: 05/09/2003
LEAD ATTORNEY

representing

**Teamsters Local No. 35 Heath
Plans**
(Consolidated Plaintiff)

ATTORNEY TO BE NOTICED

Thomas M. Sobol
Hagens Berman LLP
26th Floor
225 Franklin St.
Boston, MA 02110
617-482-3700
617-482-3003 (fax)
heatherc@hagens-berman.com
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Elliot Franklin
(Consolidated Plaintiff)

Patrick J. Lynch
(Consolidated Plaintiff)

**A.F. of L. - A.G.C. Building
Trades Welfare Plan**
(Consolidated Plaintiff)

End-Payor Plaintiffs
(Consolidated Plaintiff)

Hy-Vee, Inc.
(Consolidated Plaintiff)

**IBEW - NECA Local 505
Health & Welfare Plan**
(Consolidated Plaintiff)

**Sheet Metal Workers Local
441 Health & Welfare Plan**
(Consolidated Plaintiff)

Eugene A. Spector
Spector & Roseman
1818 Market Street
Suite 2500
Philadelphia, PA 19103
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**A.F. of L. - A.G.C. Building
Trades Welfare Plan**
(Consolidated Plaintiff)

End-Payor Plaintiffs
(Consolidated Plaintiff)

Hy-Vee, Inc.
(Consolidated Plaintiff)

IBEW - NECA Local 505
Health & Welfare Plan
(Consolidated Plaintiff)

Sheet Metal Workers Local
441 Health & Welfare Plan
(Consolidated Plaintiff)

David M. Stark
Willkie Farr & Gallagher
787 Seventh Avenue
New York, NY 10019
212-728-8000
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Teva Pharmaceutical
Industries LTD
(Consolidated Plaintiff)

Teva Pharmaceuticals USA,
Inc.
(Consolidated Plaintiff)

Archana Tamoshunas
Garwin, Bronzaft, Gerstein & Fisher
1501 Broadway
New York, NY 01002
212-391-0055
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Teva Pharmaceutical
Industries LTD
(Consolidated Plaintiff)

Teva Pharmaceuticals USA,
Inc.
(Consolidated Plaintiff)

Joseph A. Tate
Dechert LLP
4000 Bell Atlantic Tower

Query Attorneys

1717 Arch Street
Philadelphia, PA 19103-2793
Assigned: 05/17/2002
ATTORNEY TO BE NOTICED

representing

Glaxosmithkline PLC
(Defendant)

Smithkline Beecham
Corporation
(Defendant)

Michelle M. Teed
Oregon Department of Justice
1162 Court Street NE
Salem, OR 97301
503-947-4333
503-378-5017 (fax)
michelle.teed@state.or.us
Assigned: 07/26/2004
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

State of Oregon
(Intervenor Plaintiff)

Richard M. Volin
Thompson & Loughran
Duvall Foundry
1050 30th Street, N.W.
Washington, DC 20007
202-337-8000
Assigned: 12/01/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Direct Purchaser
(Consolidated Plaintiff)

Ann D. White
MAGER WHITE & GOLDSTEIN LLP
One Pitcairn Place
Suite 2400
165 Township Line Road
Jenkintown, PA 19046
215-481-0273
Assigned: 05/09/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

Barbara Brown
(Consolidated Plaintiff)

K. Craig Wildfang
Robins, Kaplan, Miller & Ciresi, L.L.P.
2800 LaSalle Plaza
800 LaSalle Avenue

End-Payor Plaintiffs

Minneapolis, MN 55402-2015
612-349-8500
612-339-4181 (fax)
Assigned: 07/26/2004
ATTORNEY TO BE NOTICED

(Consolidated Plaintiff)

representing

Pamela A. Zorn
Sherin and Lodgen LLP
101 Federal Street
Boston, MA 02110-2104
617-646-2000
617-646-2222 (fax)
pazorn@sherin.com
Assigned: 05/07/2003
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

representing

**Teva Pharmaceutical
Industries LTD**
(Consolidated Plaintiff)

**Teva Pharmaceuticals USA,
Inc.**
(Consolidated Plaintiff)

CVS Meridian, Inc.
(Consolidated Plaintiff)

Rite Aid Corp.
(Consolidated Plaintiff)

PACER Service Center			
Transaction Receipt			
08/03/2004 13:21:57			
PACER Login:	us2289	Client Code:	137420/ff5058-04
Description:	Attorney List	Case Number:	1:01-cv-12239-WGY
Billable Pages:	10	Cost:	0.70